Certain peptides and peptide copolymers composed are able to affect the activity of the CD4+ T-cells involved in the development and progression of multiple sclerosis.
Peptimmune’s most advanced drug, PI-2301, is a multiple sclerosis treatment designed to be taken weekly. It would compete with Teva Pharmaceutical Industries Ltd.’s daily treatment Copaxone, which generated $1.7 billion in sales last year. Peptimmune is counting on positive data from a study due in 2009 to show its drug is better than Copaxone.
PI-2301 is a second-generation peptide copolymer from a similar compound class as Copaxone®, and it is expected to have superior efficacy and convenience profile compared to current immunomodulating agents for the treatment of multiple sclerosis.
Read more of Peptimmune by reading >> their website <<
******************************************************************************
Then, remain up-to-date with MS News, by registering to receive
"Stu's Views and MS Related News", a weekly distributed e-Newsletter
******************************************************************************.
0 comments:
Post a Comment